This case report details the treatment of six prostate cancer patients, some with metastatic disease, using a combination of the immunomodulator IMM-101 (a heat-killed whole-cell mycobacterium), vitamin D3 correction, and anti-inflammatory agents such as bromelain and low-dose naltrexone (LDN). The combination therapy led to reductions in prostate-specific antigen (PSA) levels
